Amylin’s Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amylin and partners Eli Lilly and Alkermes plan to resubmit an application for once-weekly subcutaneous injectable Bydureon (exenatide) to FDA in the third quarter, after the candidate met the primary endpoint in a “thorough" QT study assessing cardiovascular risk, which is required for approval in the U.S.
You may also be interested in...
Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
FDA advertising regs protect Amylin's Byetta from being maligned, judge says in lifting temporary restraining order against Lilly.
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
The CHMP has recommended Bydureon for authorization, despite reservations having been expressed by FDA. An additional indication for Pradaxa was also recommended, boosting the drug's profile as a potential blockbuster.
Failed Head-To-Head Study Clouds Bydureon's Commercial Future
With competitive efficacy against successful Victoza now in doubt, Bydureon will need to differentiate itself in other ways.